{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T06:49:49Z","timestamp":1693723789228},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1097\/md.0000000000010434","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T19:57:33Z","timestamp":1523995053000},"page":"e0434","source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion"],"prefix":"10.1097","volume":"97","author":[{"given":"Yuanyuan","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianliang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-33-20210309","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/leu.2013.343","article-title":"Epigenetics of myelodysplastic syndromes","volume":"28","author":"Itzykson","year":"2014","journal-title":"Leukemia"},{"key":"R2-33-20210309","first-page":"1324","article-title":"DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias","volume":"87","author":"Leone","year":"2002","journal-title":"Haematologica"},{"key":"R3-33-20210309","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"R4-33-20210309","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2174\/156800911796798940","article-title":"Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia","volume":"11","author":"Szmigielska-Kaplon","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"R5-33-20210309","doi-asserted-by":"crossref","first-page":"41498","DOI":"10.18632\/oncotarget.17241","article-title":"Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"R6-33-20210309","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"R7-33-20210309","doi-asserted-by":"crossref","first-page":"e62924","DOI":"10.1371\/journal.pone.0062924","article-title":"Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"R8-33-20210309","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.154.1.97","article-title":"CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL","volume":"154","author":"Lanier","year":"1995","journal-title":"J Immunol"},{"key":"R9-33-20210309","first-page":"807","article-title":"Decitabine in the treatment of myelodysplastic syndromes","volume":"3","author":"Saba","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"R10-33-20210309","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"R11-33-20210309","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/15592294.2015.1062206","article-title":"DNA hypomethylation-mediated activation of cancer\/testis antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer","volume":"10","author":"Zhang","year":"2015","journal-title":"Epigenetics"},{"key":"R12-33-20210309","doi-asserted-by":"crossref","first-page":"e70522","DOI":"10.1371\/journal.pone.0070522","article-title":"Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine","volume":"8","author":"Yao","year":"2013","journal-title":"PLoS One"},{"key":"R13-33-20210309","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"R14-33-20210309","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"R15-33-20210309","doi-asserted-by":"crossref","first-page":"53654","DOI":"10.18632\/oncotarget.11183","article-title":"Decitabine-based chemotherapy followed by haploidentical lymphocyte infusion improves the effectiveness in elderly patients with acute myeloid leukemia","volume":"8","author":"Jing","year":"2017","journal-title":"Oncotarget"},{"key":"R16-33-20210309","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nm0116-8","article-title":"Take two: combining immunotherapy with epigenetic drugs to tackle cancer","volume":"22","author":"Weintraub","year":"2016","journal-title":"Nat Med"},{"key":"R17-33-20210309","first-page":"29","article-title":"Augmenting antitumor immune responses with epigenetic modifying agents","volume":"6","author":"Heninger","year":"2015","journal-title":"Front Immunol"},{"key":"R18-33-20210309","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000010434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T04:57:30Z","timestamp":1693630650000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201804200-00033"}},"subtitle":["A case report and literature review"],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":18,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000010434","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}